Metraipolis › archive › dc_1597298ec296

Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study — Europe PMC PMID:41753212

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41753212
DOI
10.3390/jcm15041525
License (as archived)
solo-consultazione
Archived
2026-11-05T19:36:25.510Z
SHA-256 of the archived text
fbae2f463d93e0de1654746dd64c6543969d5f224de0f002555429a1adceeac8
Stable URL of this page
https://metraipolis.com/documento/dc_1597298ec296

How to cite

Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study — Europe PMC PMID:41753212 — Europe PMC (en), https://europepmc.org/article/MED/41753212 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1597298ec296 (Metraipolis archive dc_1597298ec296, sha256 fbae2f463d93e0de1654746dd64c6543969d5f224de0f002555429a1adceeac8)
BibTeX
@misc{dc1597298ec296,
  title = {Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study — Europe PMC PMID:41753212},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41753212},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1597298ec296; sha256 fbae2f463d93e0de1654746dd64c6543969d5f224de0f002555429a1adceeac8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41753212. Agents can read the archived copy with the MCP tool read_document.